David Woodhouse, NGM CEO
NGM concedes key failure for their lead NASH drug, closing the door on a pivotal followup — and asking analysts to look past the wreckage into the pipeline
A little more than a year ago NGM whipped up considerable enthusiasm for its anti-fibrotic NASH drug aldafermin based on a cohort of patients who …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
